Abstract
Overview
Introduction
The report provides a comprehensive financial and strategic analysis of the
mAb market, forecasting its commercial evolution out to 2012 and assessing
trends by product, company, therapy area, technology and target type. It also
provides an insight into the direction of mAb technology evolution and an
analysis of pipeline dynamics.
Scope
- Comprehensive financial strategic analysis of the mAb market out to 2012
- Global sales forecasts to 2012 for all marketed and Phase III mAb products
- Analysis of market trends by product, company, therapy area, technology
and target type
- Analysis of characteristics of key products and insight into direction of
mAb technology evolution and pipeline dynamics
Highlights
The overall ethical pharmaceutical market is expected to face a decline in
sales over 2011 to 2012 as a result of the ' patent cliff' . The patent cliff
will impact the small molecule market, in contrast, the mAb market segment
will continue to record robust growth.
Over the period 2006-12, the mAb market segment will achieve a sales CAGR of
14.2% versus a small molecule sales CAGR of 0.6%. The main barrier to sales
growth for small molecules is exposure to material generic competition, which
will have no effect on mAbs out to 2012.
mAbs currently command a two-fold average revenue per product premium over
small molecules. Positive factors supporting this premium include a higher
demand due to addressing therapy areas of high unmet need and lower
competitive intensity due to accessing novel target space.
Reasons to Purchase
- Assess the key products that will drive sales growth in the mAb market to
2012
- Understand the challenges and barriers to entry for new players seeking to
venture into the mAb market
- Understand the nature of the generic threat across different molecule
types and the insulation of mAb products from biosimilars out to 2012
| 
View Cart
